Bruker (NASDAQ:BRKR) Sets New 52-Week High After Strong Earnings

Bruker Corporation (NASDAQ:BRKR)’s stock price hit a new 52-week high during mid-day trading on Wednesday following a stronger than expected earnings report. The company traded as high as $68.98 and last traded at $61.8820, with a volume of 1,051,428 shares. The stock had previously closed at $56.50.

The medical research company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.14. The company had revenue of $874.00 million during the quarter, compared to analyst estimates of $865.16 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%. Bruker’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.45 EPS.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st were issued a $0.05 dividend. The ex-dividend date was Monday, September 21st. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Bruker’s dividend payout ratio (DPR) is currently -28.57%.

Key Bruker News

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported Q3 earnings per share of $0.56, beating the $0.42 consensus, and revenue of $874 million versus estimates of $865.16 million. Revenue increased 1.6% year over year. The earnings and sales beats are likely the main near-term positive catalysts. Bruker Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Reports point to a return of U.S. academic demand in Q3, and Bruker is targeting double-digit EPS growth in FY2027. Improving demand and the growth target may bolster expectations for a stronger longer-term outlook. Bruker Sees U.S. Academic Demand Return
• Neutral Sentiment: FY2026 non-GAAP EPS guidance of $2.10–$2.15 brackets FactSet’s $2.12 estimate, leaving the outlook broadly in line with expectations. Bruker FY2026 EPS Guidance
• Negative Sentiment: FY2026 revenue guidance of $3.52–$3.56 billion has a midpoint below FactSet’s $3.56 billion estimate, suggesting limited near-term sales momentum. An earnings analysis also flags a steep goodwill charge, which tempers the headline results. Bruker FY2026 Revenue Guidance Bruker Q3 Margin and Goodwill Charge Analysis

Analyst Upgrades and Downgrades

Several brokerages have weighed in on BRKR. UBS Group assumed coverage on shares of Bruker in a research report on Wednesday, September 9th. They set a “neutral” rating and a $65.00 price target for the company. The Goldman Sachs Group raised shares of Bruker from a “strong sell” rating to a “strong-buy” rating in a research note on Monday, September 21st. Barclays upped their price objective on shares of Bruker from $58.00 to $70.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a report on Monday, August 31st. Finally, JPMorgan Chase & Co. cut Bruker from an “overweight” rating to a “neutral” rating and set a $60.00 target price on the stock. in a research note on Wednesday, October 14th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $59.43.

Insider Buying and Selling

In other news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the completion of the sale, the vice president directly owned 134,806 shares of the company’s stock, valued at approximately $7,127,193.22. This trade represents a 1.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 27.20% of the company’s stock.

Hedge Funds Weigh In On Bruker

A number of institutional investors have recently bought and sold shares of BRKR. Pallas Capital Advisors LLC bought a new position in Bruker in the 2nd quarter worth about $570,746,000. Edmond DE Rothschild Holding S.A. purchased a new stake in Bruker during the 2nd quarter valued at about $169,899,000. Sculptor Capital LP increased its stake in Bruker by 9.0% during the 1st quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company’s stock valued at $118,112,000 after purchasing an additional 270,000 shares in the last quarter. Alyeska Investment Group L.P. increased its stake in Bruker by 86.2% during the 2nd quarter. Alyeska Investment Group L.P. now owns 1,410,164 shares of the medical research company’s stock valued at $84,864,000 after purchasing an additional 653,007 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Bruker by 23.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,341,518 shares of the medical research company’s stock worth $84,556,000 after buying an additional 448,440 shares during the last quarter. 79.52% of the stock is owned by institutional investors.

Bruker Price Performance

The firm’s fifty day simple moving average is $58.81 and its 200-day simple moving average is $50.41. The firm has a market capitalization of $9.39 billion, a PE ratio of -88.02, a PEG ratio of 1.70 and a beta of 1.26. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.